Dr John Buscombe

British Nuclear Medicine Society

Dr John Buscombe is the President of the British Nuclear Medicine Society and works as a Consultant Physician in Nuclear Medicine in Cambridge.

dont miss

Theranostics in prostate cancer new or false dawn

Over the past 2 years new imaging and therapeutic options using radiolabelled prostate specific membrane antigen have been developed which enable us to see disease which cannot be found by other methods with gallium-68 PSMA PET-CT. Newer work has linked this to targeted radionuclide therapy using beta and alpha emitter labelled PSMA is previously untreatable metastatic prostate cancer which is being actively developed.

EVEN MORE SEMINARS

  • Sanjay Prabhu, MBBS: Speaking at the European Neurological Convention

    Sanjay Prabhu, MBBS
    Harvard Medical School / Boston Children’s Hospital

    Evolving role of machine learning in brain tumour imaging

  • Matthew Bull: Speaking at the European Neurological Convention

    Matthew Bull
    Frimley Health NHS Foundation Trust

    Pathology within the Oropharynx and Oral Cavity

  • Prof Sam Janes: Speaking at the European Neurological Convention

    Prof Sam Janes
    Delivering CT screening for Lung Cancer in the UK

    Delivering CT screening for Lung Cancer in the UK

  • Estevao Mauricio Bagi: Speaking at the European Neurological Convention

    Estevao Mauricio Bagi
    Royal Brompton & Harefield Hospitals Specialist Care

    Cardiac PET-CT : Rubidium-82 Myocardium Perfusion & 18F-FDG Cardiac Sarcoidosis

  • Dr Ben Timmis: Speaking at the European Neurological Convention

    Dr Ben Timmis
    4ways Healthcare Ltd

    How to manage x-ray reporting risk with fewer consultant radiologists